Hoth Therapeutics Raises $2M in Registered Direct Offering

Biopharmaceutical company secures funding for continued drug development and research

Apr. 2, 2026 at 8:06pm

Got story updates? Submit your updates here. ›

An extreme close-up of intricately designed metal gears and machinery, conceptually representing the institutional banking systems and financial infrastructure that power the biopharmaceutical industry.The complex financial mechanisms that fuel biopharmaceutical research and development are highlighted in this industrial-style illustration.NYC Today

Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, has announced the closing of a $2 million registered direct offering. The company issued over 2.8 million shares of common stock at $0.70 per share, along with warrants to purchase an additional 2.8 million shares at $0.85 per share. Hoth plans to use the proceeds for general corporate purposes and working capital.

Why it matters

This funding will allow Hoth Therapeutics to continue advancing its pipeline of innovative therapies targeting unmet medical needs. As a clinical-stage company, securing capital through equity offerings is crucial to supporting its research and development efforts.

The details

The registered direct offering was led by investment bank H.C. Wainwright & Co. as the exclusive placement agent. In a concurrent private placement, Hoth also issued unregistered warrants that will become exercisable in six months and expire five and a half years after issuance. The company intends to use the net proceeds for general corporate purposes, including working capital to fuel its ongoing drug development programs.

  • The offering closed on April 2, 2026.
  • The unregistered warrants will become exercisable on October 2, 2026 and expire on October 2, 2031.

The players

Hoth Therapeutics, Inc.

A clinical-stage biopharmaceutical company focused on developing innovative therapies for unmet medical needs.

H.C. Wainwright & Co.

The exclusive placement agent that led the registered direct offering for Hoth Therapeutics.

Got photos? Submit your photos here. ›

What’s next

Hoth Therapeutics plans to use the proceeds from the offering to support its ongoing drug development programs and general corporate purposes.

The takeaway

Securing $2 million in funding through a registered direct offering is a significant milestone for Hoth Therapeutics, providing the clinical-stage biopharmaceutical company with the resources to advance its pipeline of innovative therapies and continue its mission of improving patient quality of life.